Summary
patients treated
Has anyone ever benefited from stem cell?
For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples’ lives and health.
FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.
List of patients
| No. | Source | Source type | Diagnosis | Medical sector | Year of application | Therapy | Country | Age of the recipient |
|---|---|---|---|---|---|---|---|---|
| 3801 | Apheresis | Allogeneic | No Data | Hematology | 2019 | Standard Therapy | Poland | 58 |
| 3802 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 68 |
| 3803 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 28 |
| 3804 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 58 |
| 3805 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 67 |
| 3806 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 51 |
| 3807 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 65 |
| 3808 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 42 |
| 3809 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 55 |
| 3810 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 56 |
| 3811 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 59 |
| 3812 | Apheresis | Autologous | Non-Hodgkin-Lymphoma-Relapse | Hematology | 2019 | Standard Therapy | Germany | 63 |
| 3813 | Apheresis | Autologous | Non-Hodgkin-Lymphoma-Relapse | Hematology | 2019 | Standard Therapy | Germany | 69 |
| 3814 | Apheresis | Allogeneic | Osteomyelofibrosis – Other | Hematology | 2019 | Standard Therapy | Poland | 63 |
| 3815 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2019 | Standard Therapy | Poland | 70 |
| 3816 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2019 | Standard Therapy | Poland | 61 |
| 3817 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2019 | Standard Therapy | Poland | 50 |
| 3818 | Apheresis | Allogeneic | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Hematology | 2019 | Standard Therapy | Poland | 24 |
| 3819 | Apheresis | Allogeneic | Plasma Cell Leukemia | Hematology | 2019 | Standard Therapy | Poland | 35 |
| 3820 | Apheresis | Allogeneic | Polycythemia Vera-Myelofibrosis | Hematology | 2019 | Standard Therapy | Germany | 58 |
| 3821 | Apheresis | Allogeneic | Post–Polycythemia Vera Myelofibrosis | Hematology | 2019 | Standard Therapy | Germany | 70 |
| 3822 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 65 |
| 3823 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 63 |
| 3824 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 69 |
| 3825 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 64 |
| 3826 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 56 |
| 3827 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 57 |
| 3828 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 63 |
| 3829 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 67 |
| 3830 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 78 |
| 3831 | Apheresis | Allogeneic | Primary Immunodeficiency | Hematology | 2019 | Standard Therapy | Poland | 21 |
| 3832 | Apheresis | Allogeneic | Primary Immunodeficiency | Hematology | 2019 | Standard Therapy | Poland | 19 |
| 3833 | Apheresis | Allogeneic | Primary Mediastinal | Hematology | 2019 | Standard Therapy | Poland | 33 |
| 3834 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2019 | Standard Therapy | Poland | 46 |
| 3835 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2019 | Standard Therapy | Poland | 45 |
| 3836 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2019 | Standard Therapy | Germany | 55 |
| 3837 | Apheresis | Allogeneic | Relapsed Peripheral T Cell Lymphoma | Hematology | 2019 | Standard Therapy | Poland | 65 |
| 3838 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2019 | Standard Therapy | Poland | 59 |
| 3839 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2019 | Standard Therapy | Germany | 64 |
| 3840 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2019 | Standard Therapy | Germany | 60 |
| 3841 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia At Myeloproliferative Neoplasms | Hematology | 2019 | Standard Therapy | Germany | 56 |
| 3842 | Apheresis | Autologous | Secondary Primary Central Nervous System Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 66 |
| 3843 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2019 | Standard Therapy | Poland | 12 |
| 3844 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2019 | Standard Therapy | Poland | 11 |
| 3845 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2019 | Standard Therapy | Poland | 55 |
| 3846 | Apheresis | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2019 | Standard Therapy | Poland | 1 |
| 3847 | Apheresis | Allogeneic | T-Cell Acute Lymphoblastic Leukemia | Hematology | 2019 | Standard Therapy | Poland | 44 |
| 3848 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 55 |
| 3849 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 59 |
| 3850 | Apheresis | Allogeneic | T-Cell Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 67 |
| 3851 | Apheresis | Allogeneic | T-Cell Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 45 |
| 3852 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 72 |
| 3853 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 61 |
| 3854 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2019 | Standard Therapy | Germany | 61 |
| 3855 | Apheresis | Autologous | Testicular Cancer Relapse | Hematology | 2019 | Standard Therapy | Germany | 29 |
| 3856 | Apheresis | Allogeneic | Thalassemia Major | Hematology | 2019 | Standard Therapy | Poland | 20 |
| 3857 | Apheresis | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2019 | Standard Therapy | Poland | 1 |
| 3858 | Apheresis | Allogeneic | Β – Thalassemia | Hematology | 2019 | Standard Therapy | Poland | 13 |
| 3859 | Adipose Tissue | Autologous | Chondromalacia | Orthopedy | 2019 | Experimental Therapy | Poland | 48,8 |
| 3860 | Adipose Tissue | Autologous | Chondromalacia | Orthopedy | 2019 | Experimental Therapy | Poland | 38,6 |
| 3861 | Adipose Tissue | Autologous | Coxarthrosis | Orthopedy | 2019 | Experimental Therapy | Poland | 34 |
| 3862 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3863 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3864 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3865 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3866 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3867 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3868 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3869 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3870 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3871 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3872 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3873 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3874 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3875 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3876 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3877 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3878 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3879 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3880 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3881 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3882 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3883 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3884 | Adipose Tissue | Autologous | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3885 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2019 | Experimental Therapy | Poland | 44,11 |
| 3886 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2019 | Experimental Therapy | Poland | 65,3 |
| 3887 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2019 | Experimental Therapy | Poland | 68,6 |
| 3888 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2019 | Experimental Therapy | Poland | 36,1 |
| 3889 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2019 | Experimental Therapy | Poland | 54,3 |
| 3890 | Adipose Tissue | Autologous | Mild Arthritis | Orthopedy | 2019 | Experimental Therapy | Poland | 21,2 |
| 3891 | Adipose Tissue | Autologous | Mild Arthritis | Orthopedy | 2019 | Experimental Therapy | Poland | 68,5 |
| 3892 | Adipose Tissue | Autologous | Osteoarthritis | Orthopedy | 2019 | Experimental Therapy | Poland | 52,8 |
| 3893 | Adipose Tissue | Autologous | Osteoarthritis | Orthopedy | 2019 | Experimental Therapy | Poland | 44,8 |
| 3894 | Adipose Tissue | Autologous | Osteoarthritis | Orthopedy | 2019 | Experimental Therapy | Poland | 52,5 |
| 3895 | Adipose Tissue | Autologous | Osteoarthritis | Orthopedy | 2019 | Experimental Therapy | Poland | 54,5 |
| 3896 | Adipose Tissue | Autologous | Osteoarthritis | Orthopedy | 2019 | Experimental Therapy | Poland | 55,11 |
| 3897 | Adipose Tissue | Autologous | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3898 | Adipose Tissue | Autologous | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3899 | Adipose Tissue | Autologous | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3900 | Adipose Tissue | Autologous | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |